Article
Immunology
Palmira Immordino, Vincenzo Pisciotta, Emanuele Amodio, Celestino Bonura, Floriana Bonura, Federica Cacioppo, Giuseppe Calamusa, Giuseppina Capra, Alessandra Casuccio, Simona De Grazia, Dario Genovese, Davide Graci, Guido Lacca, Giuseppa Luisa Sanfilippo, Maria Gabriella Verso, Giovanni Maurizio Giammanco, Donatella Ferraro
Summary: The study compared neutralizing antibody titers against SARS-CoV-2 variants in recovered and vaccinated healthcare workers. Higher titers were observed in vaccinated individuals compared to recovered patients, indicating better efficacy of artificial immunization. This emphasizes the importance of vaccination even in individuals with previous infections.
Article
Microbiology
Szu-Wei Huang, Aspiro Nayim Urbina, Yi-Ming Arthur Chen, Sheng-Fan Wang
Summary: This study found that age is an important factor correlated with the duration of SARS-CoV-1 protective antibody existence status.
Article
Cell Biology
Kirsten E. Lyke, Robert L. Atmar, Clara Dominguez Islas, Christine M. Posavad, Daniel Szydlo, Rahul Paul Chourdhury, Meagan E. Deming, Amanda Eaton, Lisa A. Jackson, Angela R. Branche, Hana M. El Sahly, Christina A. Rostad, Judith M. Martin, Christine Johnston, Richard E. Rupp, Mark J. Mulligan, Rebecca C. Brady, Robert W. Frenck, Martin Backer, Angelica C. Kottkamp, Tara M. Babu, Kumaravel Rajakumar, Srilatha Edupuganti, David Dobrzynski, Rhea N. Coler, Janet I. Archer, Sonja Crandon, Jillian A. Zemanek, Elizabeth R. Brown, Kathleen M. Neuzil, David S. Stephens, Diane J. Post, Seema U. Nayak, Mehul S. Suthar, Paul C. Roberts, John H. Beigel, David C. Montefiori, DMID Std Grp
Summary: This study assesses the magnitude and short-term durability of neutralizing antibodies after homologous and heterologous boosting with mRNA and Ad26.COV2.S vaccines. The results show that mRNA vaccine boosting generates higher neutralizing activity against the Omicron variant compared to Ad26.COV2.S boosting. These findings have implications for protecting against Omicron and future variants of SARS-CoV-2.
CELL REPORTS MEDICINE
(2022)
Article
Immunology
Federico Pratesi, Teresita Caruso, Davide Testa, Tiziano Tarpanelli, Alessandra Gentili, Davide Gioe, Paola Migliorini
Summary: The study found that the BNT162b2 vaccine can induce high levels of antibody response in vaccinated individuals, including IgG and IgA antibodies, as well as antibodies with high avidity. Additionally, the research indicates that levels of neutralizing antibodies significantly increase after the booster dose of the BNT162b2 vaccine.
Article
Immunology
Sung-Hee Lim, Seong-Hyeok Choi, Bora Kim, Ji-Youn Kim, Young-Sok Ji, Se-Hyung Kim, Chan-Kyu Kim, Tark Kim, Eun-Ju Choo, Ji-Eun Moon, Jina Yun, Seong-Kyu Park
Summary: The study analyzed the immunogenicity and adverse events of healthcare workers vaccinated with BNT162b2 and ChAdOx1 vaccines. Results showed higher neutralizing antibody levels with BNT162b2 vaccine and more adverse events with ChAdOx1 vaccine, both of which showed high efficacy among healthcare workers at the center.
Article
Biotechnology & Applied Microbiology
Jason Z. Zhang, Hsien-Wei Yeh, Alexandra C. Walls, Basile I. M. Wicky, Kaitlin R. Sprouse, Laura A. VanBlargan, Rebecca Treger, Alfredo Quijano-Rubio, Minh N. Pham, John C. Kraft, Ian C. Haydon, Wei Yang, Michelle DeWitt, John E. Bowen, Cameron M. Chow, Lauren Carter, Rashmi Ravichandran, Mark H. Wener, Lance Stewart, David Veesler, Michael S. Diamond, Alexander L. Greninger, David M. Koelle, David Baker
Summary: The protein biosensor designed in this study utilizes thermodynamic coupling to detect neutralizing antibodies against SARS-CoV-2 variants, without the need for target modification, and can better distinguish differences between samples compared to traditional methods.
NATURE BIOTECHNOLOGY
(2022)
Article
Medicine, Research & Experimental
Jim Boonyaratanakornkit, Chihiro Morishima, Stacy Selke, Danniel Zamora, Sarah McGuffin, Adrienne E. Shapiro, Victoria L. Campbell, Christopher L. McClurkan, Lichen Jing, Robin Gross, Janie Liang, Elena Postnikova, Steven Mazur, Vladimir V. Lukin, Anu Chaudhary, Marie K. Das, Susan L. Fink, Andrew Bryan, Alex L. Greninger, Keith R. Jerome, Michael R. Holbrook, Terry B. Gernsheimer, Mark H. Wener, Anna Wald, David M. Koelle
Summary: SARS-CoV-2-specific antibodies in convalescent plasma could potentially provide protection from reinfection and disease. nAb titers correlated with COVID-19 severity, age, and sex, serving as useful surrogates for plasma donor selection. Functional nAb levels declined over time, and a small proportion of convalescent individuals lacked adaptive immune responses.
JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Microbiology
Chloe Dimeglio, Fabrice Herin, Isabelle Da-Silva, Caroline Gernigon, Marion Porcheron, Sabine Chapuy-Regaud, Jacques Izopet
Summary: This study analyzed blood samples from unvaccinated and vaccinated healthcare workers and found that the neutralizing antibody response against the SARS-CoV-2 Delta variant was 4 times less efficient compared to an earlier strain. Half of the healthcare workers had decreased protection even with the same total antibody concentration. However, the correlation between neutralization and other immune responses needs further investigation.
MICROBIOLOGY SPECTRUM
(2022)
Article
Immunology
Bram Decru, Jan Van Elslande, Sophie Steels, Gijs Van Pottelbergh, Lode Godderis, Bram Van Holm, Xavier Bossuyt, Johan Van Weyenbergh, Piet Maes, Pieter Vermeersch
Summary: This study investigated the kinetics of IgG anti-S and surrogate neutralizing antibodies in healthcare workers 3 and 10 months after natural infection or vaccination. The results showed that hybrid immunity resulted in the strongest immune response, and there was a linear relationship between surrogate neutralizing activity and log10 IgG anti-S.
FRONTIERS IN IMMUNOLOGY
(2022)
Letter
Medicine, General & Internal
Venkata Viswanadh Edara, William H. Hudson, Xuping Xie, Rafi Ahmed, Mehul S. Suthar
Summary: This study investigates the neutralizing antibody response to 4 SARS-CoV-2 variants in individuals who have been infected or vaccinated.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Microbiology
Shuting Zhang, Peijun Ma, Marek Orzechowski, Allison Lemmer, Kara Rzasa, Josephine Bagnall, Sulyman Barkho, Michael Chen, Lorri He, Raymond Neitupski, Victoria Tran, Ross Ackerman, Emily Gath, Austin Bond, Giana Frongillo, Thomas Cleland, Aaron Golas, Anthony Gaca, Michael Fitzgerald, Kathleen Kelly, Kelsey Hazegh, Larry Dumont, Corey Hoffman, Mary Homer, Peter Marks, Ann Woolley, Sharon Wong, James Gomez, Jonathan Livny, Deborah Hung
Summary: The ability to directly measure neutralizing antibodies on live SARS-CoV-2 virus in individuals can play an important role in understanding the efficacy of therapeutic interventions or vaccines. In contrast to functional neutralization assays, serological assays only quantify the presence of antibodies as a proxy of immune protection. The study developed a high-throughput, automated neutralization assay for SARS-CoV-2 and measured the neutralizing activity of over 19,000 COVID-19 convalescent plasma (CCP) samples collected across the United States between March and August of 2020.
Article
Immunology
Monica Franzese, Luigi Coppola, Romina Silva, Stefano Angelo Santini, Luigi Cinquanta, Cosimo Ottomano, Marco Salvatore, Mariarosaria Incoronato
Summary: This study monitored the antibody levels induced by the Pfizer/BioNTech mRNA BNT162b2 vaccine in healthcare workers. The third vaccine dose improved the humoral response, but the decline in antibody levels over time had a greater impact on neutralizing antibodies.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Eddy Perez-Then, Carolina Lucas, Valter Silva Monteiro, Marija Miric, Vivian Brache, Leila Cochon, Chantal B. F. Vogels, Amyn A. Malik, Elena De la Cruz, Aidelis Jorge, Margarita De los Santos, Patricia Leon, Mallery Breban, Kendall Billig, Inci Yildirim, Claire Pearson, Randy Downing, Emily Gagnon, Anthony Muyombwe, Jafar Razeq, Melissa Campbell, Albert Ko, Saad B. Omer, Nathan D. Grubaugh, Sten H. Vermund, Akiko Iwasaki
Summary: The study found that a BNT162b2 mRNA vaccine booster can enhance neutralizing antibodies against the Omicron variant in individuals who received two doses of the CoronaVac vaccine, but antibody titers remain lower compared to the ancestral virus and the Delta variant.
Article
Immunology
Stephane Marot, Isabelle Malet, Valentin Leducq, Basma Abdi, Elisa Teyssou, Cathia Soulie, Marc Wirden, Christophe Rodriguez, Slim Fourati, Jean-Michel Pawlotsky, David Boutolleau, Sonia Burrel, Vincent Calvez, Anne-Genevieve Marcelin, Aude Jary
Summary: Research found that healthcare workers who received the BNT162b2 vaccine had higher neutralizing antibody potency against SARS-CoV-2 variants compared to HCWs who had previously contracted mild forms of COVID-19.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Immunology
Jean-Louis Bayart, Jonathan Douxfils, Constant Gillot, Clara David, Francois Mullier, Marc Elsen, Christine Eucher, Sandrine Van Eeckhoudt, Tatiana Roy, Vincent Gerin, Gregoire Wieers, Christine Laurent, Melanie Closset, Jean-Michel Dogne, Julien Favresse
Summary: Data from this study showed a significant decline in antibodies levels at day 180 post SARS-CoV-2 vaccination, with a more pronounced decrease in neutralizing antibodies. The estimated half-life of IgG was around 21 days in seronegative individuals and 53 days in seropositive individuals, while the half-life of total antibodies ranged from 68 to 114 days. The decline in neutralizing antibodies was particularly stark, with around 45% of subjects testing negative at day 180.
Letter
Dermatology
Oceane Landon-Cardinal, Perrine Guillaume-Jugnot, Segolene Toquet, Nabiha Sbeih, Aude Rigolet, Nicolas Champtiaux, Karim Dorgham, Guy Gorochov, Alain Meyer, Celine Anquetil, Stephane Barete, Olivier Benveniste, Yves Allenbach
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2023)
Article
Immunology
Sandra Weller, Delphine Sterlin, Tatiana Fadeev, Eva Coignard, Alba Verge de los Aires, Clara Goetz, Remi Fritzen, Mathilde Bahuaud, Frederic Batteux, Guy Gorochov, Jean-Claude Weill, Claude-Agnes Reynaud
Summary: By sequencing the antibodies produced by B cells in humans vaccinated with Pneumovax, it was found that marginal zone (MZ) B cells play a significant role in T-independent (TI) immune responses. The study also showed that immunoglobulin M (IgM) components were already diversifying and amplifying before vaccination. These clones could be traced back mainly to MZ B cells, along with clonally related IgA+ and IgG+CD27+ B cells. Recombinant monoclonal antibodies derived from these large B cell clones were able to recognize various bacterial species in the gut, indicating the involvement of MZ and switched B cells in TI responses and their cross-reactivity with pneumococcus through somatic hypermutation.
SCIENCE IMMUNOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Adelie Gothland, Aude Jary, Philippe Grange, Valentin Leducq, Laurianne Beauvais-Remigereau, Nicolas Dupin, Anne-Genevieve Marcelin, Vincent Calvez
Summary: Reprogrammed metabolism, redox equilibrium, and ROS production play important roles in cancer development and are particularly influential in HHV-8 related diseases such as Kaposi sarcoma and primary effusion lymphoma. Primaquine diphosphate has been found to induce apoptosis in HHV-8 infected PEL cell lines through ROS production, indicating that targeting the redox balance could be a potential approach for treating HHV-8 related diseases. This review focuses on the role of ROS in cancer development and provides evidence for the importance of redox pathways in HHV-8 pathologies.
Review
Microbiology
Theophile Cocherie, Karen Zafilaza, Valentin Leducq, Stephane Marot, Vincent Calvez, Anne-Genevieve Marcelin, Eve Todesco
Summary: SARS-CoV-2 variants of concern have evolved through the accumulation of mutations in the Spike protein, which is responsible for viral binding and contains immunodominant epitopes. Different variants have emerged, each with unique characteristics in terms of transmissibility, virulence, and immune escape. The appearance of successive variants has led to the progressive improvement of SARS-CoV-2's transmissibility and its ability to evade the immune system. This review provides a comprehensive summary of the impacts of Spike mutations and the variants of concern.
Article
Microbiology
Mathieu Hubert, Florence Guivel-Benhassine, Timothee Bruel, Francoise Porrot, Delphine Planas, Jessica Vanhomwegen, Aurelie Wiedemann, Sonia Burrel, Stephane Marot, Romain Palich, Gentiane Monsel, Harouna Diombera, Sebastien Gallien, Jose Luis Lopez-Zaragoza, William Vindrios, Fabien Taieb, Sandrine Fernandes-Pellerin, Maurine Delhaye, Helene Laude, Laurence Arowas, Marie-Noelle Ungeheuer, Laurent Hocqueloux, Valerie Pourcher, Thierry Prazuck, Anne-Genevieve Marcelin, Jean-Daniel Lelievre, Christophe Batejat, Yves Levy, Jean-Claude Manuguerra, Olivier Schwartz
Summary: The third generation modified vaccinia Ankara (MVA) vaccine is effective in preventing MPXV infection. The levels of neutralizing antibodies (NAbs) are influenced by age and previous smallpox vaccination history.
CELL HOST & MICROBE
(2023)
Letter
Infectious Diseases
Aude Jary, Sokleaph Cheng, Stephane Marot, Gervillien Arnold Malonga, Theophile Cocherie, Steve Wignall, Vincent Calvez, Sophat Phal, Kem Vichet, Anne-Genevieve Marcelin, Gauthier Delvallez
JOURNAL OF INFECTION
(2023)
Article
Virology
Djeneba B. Fofana, Houdou Diarra, Ibrahima Guindo, Mahamadou K. Savadogo, Marceline d'Almeida, Fatoumata I. Diallo, Aliou Balde, Cathia Soulie, Amadou Kone, Anne-Genevieve Marcelin, Almoustapha I. Maiga, Sidonie Lambert-Niclot, Mamoudou Maiga, Sally McFall, Claudia A. Hawkins, Robert L. Murphy, Mariam Sylla, Christine Katlama, Jane L. Holl, Vincent Calvez, Laurence Morand-Joubert
Summary: Limited data exist on INI resistance in children living with HIV/AIDS in West Africa. A study was conducted on HIV-1-infected children in Benin and Mali, and it was found that no major INI resistance mutations were detected in INI-naive patients.
Article
Pharmacology & Pharmacy
Guillaume Lingas, Delphine Planas, Helene Pere, Francoise Porrot, Florence Guivel-Benhassine, Isabelle Staropoli, Darragh Duffy, Nicolas Chapuis, Camille Gobeaux, David Veyer, Constance Delaugerre, Jerome Le Goff, Prunelle Getten, Jerome Hadjadj, Adele Bellino, Beatrice Parfait, Jean-Marc Treluyer, Olivier Schwartz, Jeremie Guedj, Solen Kerneis, Benjamin Terrier
Summary: This study analyzed the kinetics of neutralizing antibody levels during acute infection with the alpha variant and showed that increases in neutralizing antibodies led to a shorter half-life of infected cells and infectious viral particles, resulting in rapid viral clearance. Simulation studies predicted that a high neutralizing activity could significantly reduce the risk of detectable viral load and infectiousness.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2023)
Letter
Infectious Diseases
Elisa Teyssou, Stephane Marot, Adelie Gothland, Isabelle Malet, Karen Zafilaza, Valentin Leducq, Theophile Cocherie, Eve Todesco, Cathia Soulie, Anne-Genevieve Marcelin, Vincent Calvez
JOURNAL OF INFECTION
(2023)
Article
Infectious Diseases
Tom Woudenberg, Laurie Pinaud, Laura Garcia, Laura Tondeur, Stephane Pelleau, Alix De Thoisy, Francoise Donnadieu, Marija Backovic, Mikael Attia, Nathanael Hoze, Cecile Duru, Aymar Davy Koffi, Sandrine Castelain, Marie-Noelle Ungeheuer, Sandrine Fernandes Pellerin, Delphine Planas, Timothee Bruel, Simon Cauchemez, Olivier Schwartz, Arnaud Fontanet, Michael White
Summary: The aim of this study was to develop a method that predicts virus neutralisation and disease protection based on variant-specific antibody measurements to SARS-CoV-2 antigens. Using a prediction model, the researchers were able to estimate population immunity and determine the vulnerability of individuals with different types of immunity. The results showed the importance of vaccination in providing strong protection against symptomatic or severe COVID-19.